Skip to main content

BVH company update

By Jamie Smith - 11 Oct 2017
Athera initiates Phase 2a trial on arterial inflammation

Athera Biotechnologies has announced that screening has started for a Phase 2a prospective, double-blind, randomised, placebo-controlled multicentre study to investigate the effects of treatment on arterial inflammation with PC-mAb.

Read more here.